Current stage, growing
With experienced leadership, a diverse pipeline of clinical assets accompanied by exclusive licensing rights, and therapies advancing to treat pervasive medical conditions, like inflammation, MS and Depression, FSD Pharma is on a strong trajectory for growth
A strong balance sheet represented by no debt and approximately 50,000,000$ CAD as of May 9th 2022
Developing novel myelin repairing compounds for the treatment of neurodegenerative and neuropsychiatric diseases
Two lead candidates leverage the power of psychedelics to improve patient outcomes and address large populations ($23B multiple sclerosis market and $238B mental health market)
Lead compound, FSD 201, a proprietary ultra micro PEA compound, has shown effective anti inflammatory properties and a favorable safety profile proving potential viability for a range of conditions
Well capitalized to pursue acquisitions that advance our mission to deliver today’s most innovative treatments for Total Brain Health
Begin the process of advancing clinical trials for its compound Lucid MS, for the novel treatment of progressive MS (Multiple Sclerosis)
Begin the process of advancing clinical trials for the treatment of depression, anxiety and psychiatric disorders through its psychedelic molecule Lucid Psych
Advancement of FSD-201 for phase 2 trials
Liquidate cash position and ability to carry out its goals without the need of further financing for at least 3 plus years